FDA — authorised 29 October 2014
- Application: NDA205649
- Marketing authorisation holder: ASTRAZENECA AB
- Status: supplemented
FDA authorised Xigduo XR on 29 October 2014
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 29 October 2014; FDA has authorised it.
ASTRAZENECA AB holds the US marketing authorisation.